FDA Warns Consumers About Unapproved Compounded GLP-1 Drugs for Weight Loss

The U.S. Food and Drug Administration (FDA) has issued a warning regarding unapproved compounded glucagon-like peptide 1 (GLP-1) drugs being marketed for weight loss. The agency has identified multiple health and safety concerns, including potential dosing errors, use of salt forms from unverified overseas factories, and reports of adverse events requiring medical intervention. The FDA has also created a 'green list' import alert to prevent unapproved GLP-1 drug ingredients from entering the U.S.